Vanguard amends Schedule 13G/A — AMPH (Vanguard reports 0 shares)
Rhea-AI Filing Summary
Amphastar Pharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Amphastar common stock as disclosed in the amendment dated 03/13/2026 and signed 03/26/2026.
The filing explains this zero ownership reflects an internal realignment at The Vanguard Group, Inc.; certain subsidiaries or business divisions now report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment lists Vanguard's voting and dispositive powers as 0 and states Vanguard's aggregate ownership is 0% of the class.
Positive
- None.
Negative
- None.
Insights
Schedules show administrative disaggregation, not a market trade.
The amendment documents an internal reallocation of reporting responsibility within The Vanguard Group under SEC Release No. 34-39538. It records 0 shares beneficially owned and zero voting/dispositive power.
This is a reporting change driven by structure; cash‑flow treatment and trading activity are not described in the excerpt. Subsequent filings by Vanguard subsidiaries may show holdings separately.
Disaggregation clarifies which Vanguard entities report holdings.
The amendment states that certain Vanguard subsidiaries or business divisions will report beneficial ownership separately and that Vanguard no longer is deemed to beneficially own those securities. This is a compliance-driven reallocation of reporting responsibility rather than a change in economic ownership as described in the excerpt.
Review later filings from named subsidiaries for the redistributed holdings and any voting‑power disclosures tied to those entities.
FAQ
What does Vanguard report for AMPH in this Schedule 13G/A?
Why does The Vanguard Group report zero ownership for AMPH?
Does the amendment indicate Vanguard sold AMPH shares?
Who signed the Schedule 13G/A for Vanguard?
Will other Vanguard filings show the redistributed AMPH holdings?